Julian Theuriet,Marion Masingue,Anthony Behin,Ana Ferreiro,Guillaume Bassez,Pauline Jaubert,Oriana Tarabay,Frédéric Fer,Antoine Pegat,Françoise Bouhour,Juliette Svahn,Philippe Petiot,Laurentiu Jomir,Guy Chauplannaz,Catherine Cornut-Chauvinc,Véronique Manel,Emmanuelle Salort-Campana,Shahram Attarian,Etienne Fortanier,Annie Verschueren,Ludivine Kouton,Jean-Philippe Camdessanché,Céline Tard,Armelle Magot,Yann Péréon,Jean-Baptiste Noury,Marie-Christine Minot-Myhie,Maud Perie,Frederic Taithe,Yacine Farhat,Anne-Laure Millet,Pascal Cintas,Guilhem Solé,Marco Spinazzi,Florence Esselin,Dimitri Renard,Sabrina Sacconi,Andra Ezaru,Edoardo Malfatti,Martial Mallaret,Laurent Magy,Eva Diab,Philippe Merle,Maud Michaud,Maxime Fournier,Aleksandra Nadaj Pakleza,Jean-Baptiste Chanson,Claire Lefeuvre,Pascal Laforet,Pascale Richard,Damien Sternberg,Rocio-Nur Villar-Quiles,Tanya Stojkovic,Bruno Eymard

Abstract:Congenital myasthenic syndromes (CMS) are clinically and genetically heterogeneous diseases caused by mutations affecting neuromuscular transmission. Even if the first symptoms mainly occur during childhood, adult neurologists must confront this challenging diagnosis and manage these patients throughout their adulthood. However, long-term follow-up data from large cohorts of CMS patients are lacking and the long-term prognosis of these patients is largely unknown. We report the clinical features, diagnostic difficulties, and long-term prognosis of a French nationwide cohort of 235 adult patients with genetically confirmed CMS followed in 23 specialized neuromuscular centres. Data were retrospectively analysed. Of the 235 patients, 123 were female (52.3%). The diagnosis was made in adulthood in 139 patients, 110 of whom presented their first symptoms before the age of 18. Mean follow-up time between first symptoms and last visit was 34 years (SD = 15.1). Pathogenic variants were found in 19 disease-related genes. CHRNE -low expressor variants were the most common (23.8%), followed by variants in DOK7 (18.7%) and RAPSN (14%). Genotypes were clustered into four groups according to the initial presentation: ocular group ( CHRNE -LE, CHRND , FCCMS), distal group (SCCMS), limb-girdle group ( RAPSN , COLQ , DOK7 , GMPPB , GFPT1 ), and a variable-phenotype group ( MUSK , AGRN ). The phenotypical features of CMS did not change throughout life. Only four genotypes had a proportion of patients requiring intensive care unit (ICU) admission that exceeded 20%: RAPSN (54.8%), MUSK (50%), DOK7 (38.6%) and AGRN (25.0%). In RAPSN and MUSK patients most ICU admissions occurred before age 18 years and in DOK7 and AGRN patients at or after 18 years of age. Different patterns of disease course (stability, improvement and progressive worsening) may succeed one another in the same patient throughout life, particularly in AGRN, DOK7 and COLQ. At the last visit, 55% of SCCMS and 36.3% of DOK7 patients required ventilation; 36.3% of DOK7 patients, 25% of GMPPB patients and 20% of GFPT1 patients were wheelchair-bound; most of the patients who were both wheelchair-bound and ventilated were DOK7 patients. Six patients died in this cohort. The positive impact of therapy was striking, even in severely affected patients. In conclusion, even if motor and/or respiratory deterioration could occur in patients with initially moderate disease, particularly in DOK7 , SCCMS and GFPT1 patients, the long-term prognosis for most CMS patients was favourable, with neither ventilation nor wheelchair needed at last visit. CHRNE patients did not worsen during adulthood and RAPSN patients, often severely affected in early childhood, subsequently improved.

Phenotypic variability in congenital myasthenic syndrome with GFPT1 mutation

Diverse myopathological features in the congenital myasthenia syndrome with GFPT1 mutation

Abnormal decrement on high-frequency repetitive nerve stimulation in congenital myasthenic syndrome with GFPT1 mutations and review of literature

Clinical and genetic characterisation of a large Indian congenital myasthenic syndrome cohort

Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review

Current status of the congenital myasthenic syndromes

Congenital myasthenic syndromes: increasingly complex

Characterization of Clinical Phenotypes in Congenital Myasthenic Syndrome Associated with the c.1327delG Frameshift Mutation in CHRNE Encoding the Acetylcholine Receptor Epsilon Subunit

Clinical features of the myasthenic syndrome arising from mutations in GMPPB

Phenotype-Genotype Correlation of a Cohort of Patients with Congenital Myopathy: A Single Centre Experience from India

Diagnostic yield of a practical electrodiagnostic protocol discriminating between different congenital myasthenic syndromes

Classification and Interpretation for 11 FBN1 Variants Responsible for Marfan Syndrome and Pre-implantation Genetic Testing (PGT) for Two Families Successfully Blocked Transmission of the Pathogenic Mutations

Current understanding of congenital myasthenic syndromes

Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis

Congenital Myasthenic Syndrome in China: Genetic and Myopathological Characterization

Novel Mutations in the C-terminal Region of GMPPB Causing Limb-Girdle Muscular Dystrophy Overlapping with Congenital Myasthenic Syndrome

Genetic analysis of a family affected by congenital myasthenic syndrome due to a Novel mutation in the SLC5A7 gene

Further observations in congenital myasthenic syndromes

Congenital myasthenic syndrome 22 due to PREPL gene mutation in 2 patients: case report and literature review

Clinical and genetic diversity in Iranian individuals with RAPSN-related congenital myasthenic syndrome

Identification of Two Novel MYH3 Variants Causing Different Phenotypes in Prenatal Diagnosis.